Loading organizations...
Veratrak develops an enterprise SaaS platform designed for the pharmaceutical supply chain, facilitating secure document sharing and master data collaboration. The company’s core offering provides comprehensive visibility and control across the entire supply chain, utilizing advanced technologies to enhance operational efficiency and data integrity for life sciences organizations. Its system is purpose-built to manage the complex data exchange requirements inherent in pharmaceutical logistics.
The company was founded in 2018 by Matthew Wilson and Jason Lacombe, emerging from the University of Oxford Foundry ecosystem. Their insight centered on the critical need to improve connectivity and security within the global pharmaceutical supply chain, addressing the fragmented data and communication challenges prevalent in the industry at the time of its inception.
Veratrak's solutions are utilized by participants across the healthcare and pharmaceutical sectors, including manufacturers, distributors, and logistics partners. The company's vision is to establish a more integrated, efficient, and secure environment for the global pharmaceutical supply chain, ensuring that sensitive data and critical information flow seamlessly and safely between all stakeholders, contributing to a more resilient pharmaceutical ecosystem.
Veratrak has raised $7.8M across 3 funding rounds.
Veratrak has raised $7.8M in total across 3 funding rounds.
Veratrak is a UK-based software company founded in 2018 that builds a blockchain-based SaaS platform for pharmaceutical supply chain management. It serves life sciences firms, including pharma manufacturers, CDMOs (Contract Development and Manufacturing Organizations), CPOs (Contract Packaging Organizations), and logistics partners, by enabling secure, compliant data exchange and collaboration across global networks.[1][2][3][4][6] The platform solves critical problems like manual workflows, supply chain blind spots, regulatory compliance (e.g., GAMP 5, EU GMP Annex 11, FDA 21 CFR Part 11), and data silos by providing real-time visibility, auditable digital transactions, ERP integrations, and AI-enabled insights—replacing paper-based processes with immutable blockchain tracking for documents like purchase orders and audit trails.[1][3][4][5][6] With over 200 partners across six continents and rapid adoption (e.g., streamlined workflows at clients like Tjoapack), Veratrak demonstrates strong growth momentum in digitizing highly regulated supply chains.[1][2]
Veratrak emerged from the University of Oxford Foundry ecosystem in 2018, co-founded by Jason Lacombe (CEO) and Matthew Wilson, who aimed to digitize pharmaceutical supply chains for better auditing, compliance, and efficiency.[3][4] Lacombe and Wilson, industry experts, identified the need to move from paper to secure digital platforms amid regulatory demands, developing a GAMP 5-compliant solution tested with pharma users.[4][6] Early traction came from partnerships with over 150-200 organizations globally, including logistics firms, and pioneering live blockchain in production—pivotal for proving immutable workflows in a sector plagued by manual exchanges.[1][2][3][4] This foundation has fueled expansion, with the small team (under 25 employees) now hiring amid "extraordinary demand" for innovative tools.[2][3]
Veratrak rides the blockchain-for-supply-chain transparency trend in life sciences, amplified by post-pandemic resilience needs, regulatory pressures (e.g., serialization, traceability), and digital transformation in pharma manufacturing.[1][3][4][6] Timing is ideal amid M&A-driven system fragmentation and outsourced models, where market forces like rising costs and global disruptions favor platforms reducing inefficiencies—Veratrak's early blockchain adoption sets a "new standard" for secure, auditable exchanges.[1][3][6] It influences the ecosystem by connecting 200+ partners across continents, enabling pharma firms to orchestrate external networks, benchmark AI/digital maturity, and pioneer compliant tech—positioning it against competitors like GHX or Model N in revenue optimization.[1][5]
Veratrak is poised to become the "default integration platform" for pharma external manufacturing, expanding AI-driven insights, global partnerships, and product innovations amid surging demand.[3][6] Trends like AI-enhanced visibility, stricter compliance, and resilient outsourcing will propel growth, potentially scaling its small team and revenue (currently under $5M) through deeper ERP ties and telco-adjacent expansions.[2][1] Its influence may evolve by standardizing blockchain in life sciences, empowering more affordable, high-quality medicine delivery—building on its Oxford roots to lead supply chain digital resilience.[3][4][7]
Veratrak has raised $7.8M across 3 funding rounds. Most recently, it raised $6.5M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 31, 2023 | $6.5M Seed | TrueSight Ventures | — | Announced |
| Apr 1, 2019 | $1M Seed | Force Over Mass | Albion VC, Angel Investment Network, Lionheart Ventures, Oxford Science Enterprises, Playfair Capital, Seedcamp, YAS Investments, Fritz Demopoulos, Paul Forster, Will Brooks, Will Martin, Antonin DE Fougerolles, Charlie Songhurst, Tony Fitzpatrick, Ascension Ventures, Blockchain Valley Ventures, TrueSight Ventures | Announced |
| Apr 1, 2018 | $250K Seed | — | Seedcamp | Announced |
Veratrak has raised $7.8M in total across 3 funding rounds.
Veratrak's investors include TrueSight Ventures, Force Over Mass, Albion VC, Angel Investment Network, Lionheart Ventures, Oxford Science Enterprises, Playfair Capital, Seedcamp, YAS Investments, Fritz Demopoulos, Paul Forster, Will Brooks.
